While the role of apolipoproteins and low-density lipoproteins (LDL) in cardiovascular disease (CVD) has been understood for some time, emerging research is revealing that these proteins may prove to be valuable biomarkers beyond CVD. They are now linked to cancer, autoimmunity, neurodegeneration, and other chronic diseases.
What are apolipoproteins?
Along with other proteins, apolipoproteins bind lipids to form lipoproteins such as high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL). These lipoproteins are then responsible for transporting lipids throughout the lymphatic and circulatory systems. There are eight classes of apolipoproteins with many subclasses, and each has a unique function in maintaining health or driving disease (Table 1). A large body of work has linked various apolipoproteins to neurodegenerative and cardiovascular diseases. However, recent studies indicate that apolipoproteins are critical biomarkers in many other diseases, from autoimmunity to cancer (Table 2).
Table 1. An overview of apolipoproteins.
|Analyte||Gene ID||UniProt ID||Description|
|Apo A1||335||P02647||Major protein component of HDL particles in plasma.|
|Apo A2||336||P02652||Found in HDL cholesterol in plasma.|
|Apo B||338||P04114||Primary organizing protein component of the shell enclosing fat molecules, and is absolutely required for the formation of LDL, VLDL, and intermediate-density lipoprotein (IDL).|
|Apo C1||341||P02654||Expressed primarily in the liver and activated when monocytes differentiate into macrophages.|
|Apo C3||345||P02656||A component of VLDL that inhibits lipoprotein lipase and hepatic lipase. It is thought to inhibit hepatic uptake of triglyceride-rich particles.|
|Apo D||347||P05090||A component of HDL that has no marked similarity to other apolipoprotein sequences. It has a high degree of homology to plasma retinol-binding protein, also known as lipocalins. Apo D is also closely associated with the enzymes involved in lipoprotein metabolism.|
|Apo E||348||P02649||Expressed by the liver and macrophages, it is primarily found in IDL that are essential for the normal catabolism of triglyceride-rich lipoprotein constituents in peripheral tissues. In the central nervous system, Apo E is mainly produced by astrocytes and transports cholesterol to neurons via Apo E receptors. ApoE is the principal cholesterol carrier in the brain.|
|Apo H||350||P02749||One of its functions is to bind cardiolipin. When bound the structure of cardiolipin and Apo H both undergo large changes in structure that allow for involvement in phospholipid binding. Apo H has a complex involvement in the agglutination of platelets. Normally, Apo H assumes an anti-coagulation activity in serum. However, changes in blood factors can result in a reversal of that activity.|
|Apo J||1191||P10909||Also known as clusterin, Apo J is associated with the clearance of cellular debris and apoptosis. In humans, it is a molecular chaperone responsible for aiding protein folding of secreted proteins. Its three isoforms have been differentially implicated in pro- or anti-apoptotic processes.|
Table 2. The scientific literature on apolipoproteins in disease, from 1972–2017.
Percent of publications that mention the target within the disease subgroup. Articles (8,027) were filtered from PubMed (1/1/1972 – 8/16/17) for mention of any of the listed targets.
Apolipoproteins serve as biomarkers for assessing risk or protection in cardiovascular disease
Specific apolipoproteins have been identified as key markers of cardiovascular risk. The apolipoprotein B (Apo B): apolipoprotein A1 (Apo A1) ratio was shown to be superior to HDL and LDL cholesterol ratios for estimating the risk of acute myocardial infarction (McQueen et al. 2008). High serum levels of both Apo B and Apo A1 are also linked to the development of atherosclerosis (Olsen et al. 2017). The correlation between Apo B and cardiovascular disease (CVD) has been demonstrated across all ethnic groups and sexes (McQueen et al. 2008). It is also a greater indicator of atherogenesis in individuals 40 years and younger, compared to older individuals (Sniderman et al. 2016). This therefore serves as a measure for initiating lipid-lowering therapy in these patients (Sniderman et al. 2016).
In contrast, low levels of apolipoprotein C3 (Apo C3) are associated with cardiovascular protection (Ooi et al. 2008). A recent study identified an Apo C3 variant called D25V that was highly concentrated within amyloid fibrils. It was shown that D25V causes a unique case of amyloidosis in a number of tissues, including the heart (Valleix et al. 2016). It is likely that fibrate therapy could be used to address this new kind of amyloidosis; but further research is needed to confirm this hypothesis (Valleix et al. 2016).
While cholesterol levels are still used to measure cardiovascular risk, apolipoproteins have emerged as relevant biomarkers for assessing the risk of various CVD and initiating prophylactic and therapeutic strategies.
Genetic variants of apolipoprotein E confer increased risk or protection in Alzheimer’s disease
The apolipoprotein gene E (APOE) has been identified as the most significant genetic risk factor for late-onset Alzheimer’s disease (LOAD) (Corder et al. 1993, Strittmatter et al. 1993). There are different alleles of the APOE gene; however three are more prevalent in the general population: APOE ε2, APOE ε3, and APOE ε4. While APOE ε3 demonstrates neutral effects on the development of LOAD, APOE ε4 has been shown to increase the risk of disease and APOE ε2 has protective effects (Huynh et al. 2017). The APOE ε4 variant is found in approximately 25–30% of the population and in around 40% of individuals with LOAD (van Duijn et al. 1994). As a result, APOE ε4 testing is currently used in clinical research settings to identify patients with an increased risk of developing LOAD (Huynh et al. 2017).
Although APOE is the strongest known risk factor for LOAD, the mechanisms by which it leads to the disease are still poorly defined. A recent study demonstrated that APOE ε2, APOE ε3, and APOE ε4 have different abilities to transfer lipids from neurons to glia, and thus differ in their capacity to mitigate the accumulation of lipid droplets, which could lead to LOAD (Liu et al. 2017). APOE ε2 and APOE ε3 can effectively transfer lipids into glia, whereas APOE ε4 is impaired in its ability to carry out this task (Liu et al. 2017). Further research is therefore needed to fully understand the role of APOE in LOAD in order to determine its potential as a therapeutic target. However, it is likely that introducing APOE ε2 phenotypes in at-risk individuals could be a useful strategy to treat LOAD (Keeney et al. 2015).
Apolipoprotein J (Apo J, clusterin) has also been implicated in Alzheimer’s disease (AD). In 1992, it was suggested as a potential biomarker for AD. However, subsequent studies between 2010 and 2016 have demonstrated conflicting results as to its role in this disease (Woody and Zhao 2016). Differences in the findings are linked to variation in samples and sample size; therefore a more comprehensive study is needed to determine the potential of Apo J as a biomarker for AD (Woody and Zhao 2016).
Apolipoproteins are involved in the development and progression of type II diabetes
The incidence of type II diabetes (T2D) has been increasing globally, which has led to major efforts to identify markers that determine risk. Similar to CVD, the Apo B:Apo A1 ratio is associated with the development of T2D, and has been proposed as a new biomarker for predicting the disease (Mao et al. 2017, Zheng et al. 2017). High concentrations of Apo A1 were found to be predictive of T2D and demonstrated a significant linear association that was superior to other lipid and lipoprotein variables (Jian et al. 2013, Onat et al. 2010).
Apo C3 has also recently been identified as a novel biomarker involved in the pathogenesis of diabetes (Aroner et al. 2017). It was shown that Apo C3 on its own is a strong risk marker. Serum levels of Apo C3 as well as the Apo C3:Apo A1 ratio were associated with the incidence of T2D (Brahimaj et al. 2016). These findings suggest that Apo C3 could be a useful therapeutic target for diabetes (Aroner et al. 2017).
The APOE ε2 allele has been shown to confer only a moderate risk to the development of T2D (Anthopoulos et al. 2010). However, further research is needed to determine the metabolic mechanism of this association.
Apolipoproteins are involved in tumor development and metastasis and serve as diagnostic biomarkers
Lipid metabolism has been implicated as a major metabolic pathway in cancer (Baenke et al. 2013). Accordingly, several recent studies have investigated the association between proteins involved in lipid metabolism, such as lipids and apolipoproteins, and cancer risk and progression. While Apo A1 and Apo B are firmly established in CVD, they also play a role in cancer development. It is suggested that Apo A1 and Apo B100 might provide superior risk prediction for certain cancers than standard lipid markers (Chandler et al. 2016).
The Malmo Diet and Cancer study of over 28,098 individuals demonstrated a positive correlation between the Apo B:Apo A1 ratio as well as Apo B and overall cancer incidence (Borgquist et al. 2016). The association between Apo A1 and cancer risk has been further demonstrated in lung, pancreatic, colon, and ovarian cancer as well as metastatic nasopharyngeal carcinoma (Borgquist et al. 2016, Zamanian-Daryoush and DiDonato 2015).
Based on these results, Apo A1 along with transthyretin, transferrin, HDL-associated proteins, β2-microglobulin, prealbumin, and CA125 is currently part of a U.S. Food and Drug Administration approved plasma test to identify patients with early stage ovarian cancer (Zamanian-Daryoush and DiDonato 2015). Similarly, Apo A1 mimetic peptides have also been evaluated in mouse tumor models and shown to reduce tumor growth, inhibit angiogenesis, and abrogate growth factor-induced proliferation, migration, and invasion. These studies suggest that Apo A1 is a key therapeutic molecule for cancer detection and treatment (Zamanian-Daryoush and DiDonato 2015).
Interestingly, apolipoprotein E (Apo E), known for its involvement in AD, has recently attracted attention as a major protein associated with tumorigenesis and metastasis (Luo et al. 2016). High serum Apo E levels in non-small cell lung cancer patients were associated with lymph node metastasis, distant metastasis, and TNM stage, which describe how far a tumor has progressed (Luo et al. 2016). Further research is needed to confirm the role of Apo E in other cancers; however, serum Apo E may act as a useful clinical serological biomarker for evaluating tumor progression (Luo et al. 2016).
Apolipoprotein concentrations are important in systemic inflammatory conditions such as sepsis
A number of studies have identified specific apolipoproteins as biomarkers in inflammation and sepsis. For instance, apolipoprotein M (Apo M) levels were shown to be dramatically reduced in patients with sepsis and systemic inflammatory response syndromes (SIRS) (Kumaraswamy et al. 2012). Apo M contributes to the anti-inflammatory response. Therefore, its reduced expression is considered a biomarker for sepsis and SIRS (Kumaraswamy et al. 2012).
Reduced levels of Apo C3 have also been implicated in inflammation (Morin et al. 2015). An Apo C3-2:Apo C3-1 ratio higher than 1.25 was shown to indicate increased risk of death in severe sepsis patients younger than 49 years old (Morin et al. 2015). In contrast, high levels of Apo C1 were detected in older adults, who developed severe sepsis (Morin et al. 2015). Furthermore, higher levels of Apo E3 were shown to reduce the risk of severe sepsis (Chuang et al. 2010).
Other studies have investigated the therapeutic potential of Apo A1 to treat sepsis and inflammation. In rat models of sepsis associated with acute respiratory distress syndrome, administration of an Apo A1 mimetic peptide (L-4F) protected animals from progressive inflammation (Sharifov et al. 2013). This suggests that these mimetic peptides could be further developed as effective treatment for systemic inflammatory disease. This is supported by another study showing that overexpression of Apo A1 in mice protects against septic death (Morin et al. 2015). However, further clinical research is necessary to thoroughly evaluate the therapeutic potential of Apo A1.
The global incidence of chronic diseases has been increasing, which has led to major efforts to reduce risk and develop novel therapies. The identification of useful biomarkers is critical for developing better treatment, and apolipoproteins have been shown to be useful biomarkers in a number of diseases. Yet, thorough investigation is needed to fully understand their role in disease and exploit this information for effective prevention and treatment strategies.
To support scientists in their effort to understand apolipoproteins in health and disease, Bio-Rad has developed the Bio-Plex Pro™ Human Apolipoprotein Assay Panel. This panel allows sensitive detection and quantification of ten apolipoprotein analytes including Apo A1, Apo C1, Apo C3, Apo E, and Apo J, which are mentioned in this article.
Learn more about this apolipoprotein magnetic bead-based multiplex assay.
Anthopoulos PG et al. (2010). Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. Mol Genet Metab 100, 283–291.
Aroner SA et al. (2017). Apolipoprotein C-III and high-density lipoprotein subspecies defined by apolipoprotein C-III in relation to diabetes risk. Am J Epidemiol 186, 736–744.
Baenke F et al. (2013). Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech 6, 1353–1363.
Borgquist S et al. (2016). Apolipoproteins, lipids and risk of cancer. Int J Cancer 138, 2648–2656.
Brahimaj A et al. (2016). Serum levels of apolipoproteins and incident type 2 diabetes: A prospective cohort study. Diabetes Care 40, 346–351.
Chandler PD et al. (2016). Lipid biomarkers and long-term risk of cancer in the Women’s Health Study. Am J Clin Nutr 103, 1397–1407.
Chuang K et al. (2010). An expanding role for apolipoprotein E in sepsis and inflammation. Am J Surg 200, 391–397.
Corder EH et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923.
Huynh TV et al. (2017). Apolipoprotein E and Alzheimer disease: The influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J Lipid Res 58, 824–836.
Jian ZH et al. (2013). The association between the apolipoprotein A1/ high density lipoprotein-cholesterol and diabetes in Taiwan— a cross-sectional study. BMC Endocr Disord 13, 42.
Keeney JT et al. (2015). Human ApoE isoforms differentially modulate glucose and amyloid metabolic pathways in female brain: Evidence of the mechanism of neuroprotection by ApoE2 and implications for Alzheimer’s disease prevention and early intervention. J Alzheimers Dis 48, 411–424.
Kumaraswamy SB et al. (2012). Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes. Crit Care 16, R60.
Liu L et al. (2017). The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D. Cell Metab [published online ahead of print September 28, 2017]. Accessed October 17, 2017.
Luo J et al. (2016). Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer. Tumour Biol 37, 10,715–10,721.
Mao Y et al. (2017). The nonlinear association between apolipoprotein B to apolipoprotein A1 ratio and type 2 diabetes. Medicine (Baltimore) 96, e5834.
McQueen MJ et al. (2008). Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infection in 52 countries (the INTERHEART study): a case-control study. Lancet 372, 224–233.
Morin EE et al. (2015). HDL in sepsis — risk factor and therapeutic approach. Front Pharmacol 6, 244.
Olsen T et al. (2017). Cardiovascular disease risk associated with serum apolipoprotein B is modified by serum vitamin A. Atherosclerosis 265, 325–330.
Onat A et al. (2010). The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 142, 72–79.
Ooi et al. (2008). Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci 114, 611–624.
Sharifov OF et al. (2013). Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis. PLoS One 8, e64486.
Sniderman AD et al. (2016). Age and cardiovascular risk attributable to apolipoprotein B, low‐density lipoprotein cholesterol or non‐high‐density lipoprotein cholesterol. J Am Heart Assoc 5, e003665.
Strittmatter WJ et al. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977–1981.
Valleix S et al. (2016). D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nat Commun 7, 10353.
van Duijn CM et al. (1994). Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer’s disease. Nat Genet 7, 74–78.
Woody SK and Zhao L (2016). Clusterin (APOJ) in Alzheimer’s disease: An old molecule with a new role. In Update on Dementia, D.V. Moretti, ed. (InTech: open access), pp. 327–330.
Zamanian-Daryoush M and DiDonato JA (2015). Apolipoprotein A-I and cancer. Front Pharmacol 6, 265.
Zheng S et al. (2017). Associations of apolipoprotein B/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: A cross-sectional study in Chinese adults. BMJ Open 7, e014038.
The Bio-Plex Suspension Array System includes fluorescently labeled microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation.